DBP International AB: European patent for the technology platform BeloGal® is granted
Double Bond Pharmaceutical International AB (publ) ("DBP" or the "Company", org. no. 556991-6082) has today, May 29, 2024, received information about the granting of a European patent application for organ-specific administration of hydrophilic cancer drugs to the liver. This applies, among other things, to one of the company's frontline products SA-033 for the treatment of liver cancer, which is based on the technology platform BeloGal®. The patent approval means protection for the product in 26 countries within the European Patent Office (EPO) at least until the year 2035. "The granted